

## Publikationsliste

Stand: 08/2025

### 1. Originalarbeiten

---

1. Diebold M, Enzler-Tschudy A, Helmchen BM, Hopfer H, Kim MJ, Moll S, Nanchen G, Rotman S, Seeger H, **Kistler AD**. Incidence of Common Glomerular Diseases Other Than Collapsing Glomerulopathy is Not Increased After SARS-CoV-2 Infection. *Kidney Int Rep*. 2024;9(4):1122-1126. <https://pubmed.ncbi.nlm.nih.gov/38765571/>
2. Komminoth M, Donath M, Aeberli D, Villiger PM, Braendle M, Schuetz P, Mueller B, Blum C, Henzen C, Leuppi JD, **Kistler AD**, Thurnheer R, Beuschlein F, Rodofsky G, Hepprich M, Reny JM, Gosselin P, Boehm S, Chifu I, Fassnacht M, Meyer G, Bojunga J, Gattaneo M, Sluka C, Colosky M, Schneider H, Rutishauser J. Glucocorticoid withdrawal and glucocorticoid-induced adrenal insufficiency: study protocol of the randomized controlled „TOASST“ (Taper Or Abrupt Steroid STop) multicenter trial. *PLoS One*, *PLoS One*. 2023;18(4):e0281585. <https://pubmed.ncbi.nlm.nih.gov/37018188/>
3. Weber MR, Diebold M, Wiesli P, **Kistler AD**. Accuracy of Flash Glucose Monitoring in Hemodialysis Patients With and Without Diabetes Mellitus. *Exp Clin Endocrinol Diabetes*. 2023;131(3):132-141. <https://pubmed.ncbi.nlm.nih.gov/36377191/>
4. Schultes B, Emmerich S, **Kistler AD**, Mecheri B, Schnell O, Rudofsky G. Impact of Albumin-to-Creatinine Ratio Point-of-Care Testing on the Diagnosis and Management of Diabetic Kidney Disease. *J Diabetes Sci Technol*. 2023;17(2):428-438. <https://pubmed.ncbi.nlm.nih.gov/34709065/>
5. Diebold M, Locher E, Boide P, Enzler-Tschudy A, Faivre A, Fischer I, Helmchen B, Hopfer H, Kim MJ, Moll S, Nanchen G, Rotman S, Saganas C, Seeger H, **Kistler AD**. Incidence of new onset glomerulonephritis after SARS-CoV-2 mRNA vaccination is not increased. *Kidney Int*. 2022;102(6):1409-1419. <https://pubmed.ncbi.nlm.nih.gov/36096267/>
6. Olinger E, Schaeffer C, Kidd K, Elhassan EAE, Cheng Y, Dufour I, Schiano I, Mabillard H, Pasqualetto E, Hofmann P, Fuster DG, **Kistler AD**, Wilson IJ, Kmoch S, Raymond L, Robert T, Eckardt KU, Bleyer AJ Sr, Kottgen A, Conlon PJ, Wiesener M, Sayer JA, Rampoldi L, Devuyst O. An intermediate effect size variant in *UMOD* confers risk for chronic kidney disease. *Proc Natl Acad Sci U S A*. 2022;119(33):e2114734119. <https://pubmed.ncbi.nlm.nih.gov/35947615/>
7. Bock L, Keil A, Flury S, **Kistler AD**. Treatment of Metabolic Acidosis in Hemodialysis patients is Biased by Type of Vascular Access. *Kidney Int Rep*. 2022;7(7):1694-1698. <https://pubmed.ncbi.nlm.nih.gov/35812293/>
8. Mohamed R, Liu Y, **Kistler AD**, Harris PC, Thangaraju M. Netrin-1 Overexpression Induces Polycystic Kidney Disease: A Novel Mechanism Contributing Cystogenesis in Autosomal Dominant Polycystic Kidney Disease. *Am J Pathol*. 2022:S0002-9440(22)00104-3. <https://pubmed.ncbi.nlm.nih.gov/35358475/>
9. Nowak A, Haddad G, **Kistler AD**, Nlandu-Khodo S, Beuschlein F, Wüthrich RP, Lorenzen JM, Kölling M. Circular RNA-based biomarkers in blood of patients with Fabry disease and related phenotypes. *J Med Genet*. 2022;59(3):279-286. <https://pubmed.ncbi.nlm.nih.gov/33547137/>

10. Haddad G, Lorenzen JM, Ma H, de Haan N, Seeger H, Zaghrini C, Brandt S, Kölling M, Wegmann U, Kiss B, Pál G, Gál P, Wüthrich RP, Wuhrer M, Beck LH, Salant DJ, Lambeau G, **Kistler AD**. Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy. *J Clin Invest*. 2021;131(5):e140453. <https://pubmed.ncbi.nlm.nih.gov/33351779/>
11. Haddad G, Kölling M, Wegmann UA, Dettling A, Seeger H, Schmitt R, Soerensen-Zender I, Haller H, **Kistler AD**, Dueck A, Engelhardt S, Thum T, Mueller TF, Wüthrich RP, Lorenzen JM. Renal AAV2-Mediated Overexpression of Long Non-Coding RNA *H19* Attenuates Ischemic Acute Kidney Injury Through Sponging of microRNA-30a-5p. *J Am Soc Nephrol*. 2021;32(2):323-341. <https://pubmed.ncbi.nlm.nih.gov/33478972/>
12. Bonani M, Seeger H, Weber N, Lorenzen JM, Wüthrich RP, **Kistler AD**. Safety of kidney biopsy when performed as an outpatient procedure. *Kidney Blood Press Res*. 2021;46(3):310-322. <https://pubmed.ncbi.nlm.nih.gov/34077930/>
13. Pokidysheva E, Seeger H, Pedchenko V, Chetyrkin SV, Bergmann C, Abrahamson D, Cui Z, Delpire E, Fervenza F, Fidler AL, Fogo AB, Gaspert A, Grohmann M, Gross O, Haddad G, Harris R, Kashtan C, Kitching R, Lorenzen JM, McAdoo S, Pusey C, Segelmark M, Simmons A, Voziyan P, Wagner T, Wüthrich RP, Zhao M, Boudko S\*, **Kistler AD\***, Hudson BG\* (\*Co-senior authors). Mechanisms of Collagen IV $\alpha^{345}$  assembly and dysfunction in Goodpasture's and Alport diseases. I. A COL4A3 variant illuminates molecular pathogenesis. *J Biol Chem*. 2021;296:100590. <https://pubmed.ncbi.nlm.nih.gov/33774048/>
14. Olinger E, Hofmann P, Kidd K, Dufour I, Belge H, Schaeffer C, Kipp A, Bonny O, Deltas C, Demoulin N, Fehr T, Fuster DG, Gale DP, Goffin E, Hodaňová K, Huynh-Do U, **Kistler A**, Morelle J, Papagregoriou G, Pirson Y, Sandford R, Sayer JA, Torra R, Venzin C, Venzin R, Vogt B, Živná M, Greka A, Dahan K, Rampoldi L, Kmoch S, Bleyer AJ Sr, Devuyst O. Clinical and genetic spectra of autosomal dominant tubulointerstitial kidney disease due to mutations in UMOD and MUC1. *Kidney Int*. 2020;98(3):717-731. <https://pubmed.ncbi.nlm.nih.gov/32450155/>
15. Randi EB, Vervaeke B, Tsachaki M, Porto E, Vermeulen S, Lindenmeyer MT, Thuy LTT, Cohen CD, Devuyst O, **Kistler AD**, Szabo C, Kawada N, Hankeln T, Odermatt A, Dewilde S, Wenger RH, Hoogewijs D. The Antioxidative Role of Cytochrome c in Podocytes: Implications for a Role in Chronic Kidney Disease. *Antioxid Redox Signal*. 2020;32(16):1155-1171. <https://pubmed.ncbi.nlm.nih.gov/31910047/>
16. Kölling M, Haddad G, Wegmann U, **Kistler A**, Bosakova A, Seeger H, Hübel K, Haller H, Mueller T, Wüthrich RP, Lorenzen JM. Circular RNAs in Urine of Kidney Transplant Patients with Acute T Cell-Mediated Allograft Rejection. *Clin Chem*. 2019;65(10):1287-1294. <https://pubmed.ncbi.nlm.nih.gov/31371281/>
17. Diebold M, **Kistler AD**. Evaluation of Iron Stores In Hemodialysis Patients On Maintenance Ferric Carboxymaltose Dosing. *BMC Nephrology*. 2019;20(1):76. <https://pubmed.ncbi.nlm.nih.gov/30823916/>
18. Kölling M, Seeger H, Haddad G, **Kistler A**, Nowak A, Faulhaber-Walter R, Kielstein J, Haller H, Fliser D, Mueller T, Wüthrich RP, Lorenzen JM. The Circular RNA *ciRs-126* Predicts Survival in Critically Ill Patients With Acute Kidney Injury. *Kidney Int Rep*. 2018;3(5):1144-1152. <https://pubmed.ncbi.nlm.nih.gov/30197981/>
19. Kölling M, Genschel C, Kaucsar T, Hübner A, Rong S, Schmitt R, Sørensen-Zender I, Haddad G, **Kistler A**, Seeger H, Kielstein JT, Fliser D, Haller H, Wüthrich R, Zörnig M, Thum T, Lorenzen J. Hypoxia-induced long non-coding RNA Malat1 is dispensable for renal ischemia/reperfusion-injury. *Sci Rep*. 2018;8(1):3438. <https://pubmed.ncbi.nlm.nih.gov/29467431/>
20. Pejchinovski M, Siwy J, Metzger J, Dakna M, Mischak H, Klein J, Jankowski V, Bae KT,

Chapman AB, **Kistler AD**. Urine peptidome analysis predicts risk of end-stage renal disease and reveals proteolytic pathways involved in autosomal dominant polycystic kidney disease progression. *Nephrol Dial Transplant*. 2017;32(3):487-497. <https://pubmed.ncbi.nlm.nih.gov/27382111/>

21. Yu H, **Kistler A**, Faridi MH, Meyer JO, Trynieszewska B, Mehta D, Yue L, Dryer S, Reiser J. Synaptopodin Limits TRPC6 Podocyte Surface Expression and Attenuates Proteinuria. *J Am Soc Nephrol*. 2016;27(11):3308-3319. <https://pubmed.ncbi.nlm.nih.gov/27020855/>
22. **Kistler AD**, Caicedo A, Abdulreda MH, Faul C, Kerjaschki D, Berggren PO, Reiser J, Fornoni A. In vivo imaging of kidney glomeruli transplanted into the anterior chamber of the mouse eye. *Sci Rep*. 2014;4:3872. <https://pubmed.ncbi.nlm.nih.gov/24464028/>
23. **Kistler AD**, Singh G, Pippin J, Altintas MM, Yu H, Fernandez IC, Gu C, Wilson C, Srivastava SK, Dietrich A, Walz K, Kerjaschki D, Ruiz P, Dryer S, Sever S, Dinda AK, Faul C, Shankland SJ, Reiser J. TRPC6 protects podocytes during complement-mediated disease. *J Biol Chem*. 2013;288(51):36598-609. <https://pubmed.ncbi.nlm.nih.gov/24194522/>
24. **Kistler AD**, Serra AL, Siwy J, Poster D, Krauer F, Torres VE, Mrug M, Grantham JJ, Bae KT, Bost JE, Mullen W, Wüthrich RP, Mischak H and Chapman AB. Urinary proteomic biomarkers enable diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multi-centric study. *PLoS One*. 2013;8(1):e53016. <https://pubmed.ncbi.nlm.nih.gov/23326375/>
25. Braun M, Young J, Reiner CS, Poster D, Krauer F, **Kistler AD**, Kristanto P, Wang X, Liu Y, Loffing J, Andreisek G, von Eckardstein A, Senn O, Wüthrich RP, Serra AL. Low-Dose Oral Sirolimus and the Risk of Menstrual-Cycle Disturbances and Ovarian Cysts: Analysis of the Randomized Controlled SUISE ADPKD Trial. *PLoS One*. 2012;7(10):e45868. <https://pubmed.ncbi.nlm.nih.gov/23071528/>
26. Mohebbi N, Vargas-Poussou R, Hegemann SC, Schuknecht B, **Kistler AD**, Wüthrich RP, Wagner CA. Homozygous and compound heterozygous mutations in the ATP6V1B1 gene in patients with renal tubular acidosis and sensorineural hearing loss. *Clin Genet*. 2013;83(3):274-8. <https://pubmed.ncbi.nlm.nih.gov/22509993/>
27. Pavik I, Jaeger P, Ebner L, Poster D, Krauer F, **Kistler AD**, Rentsch K, Andreisek G, Wagner CA, Devuyst O, Wüthrich RP, Schmid C, Serra AL. Soluble Klotho and Autosomal Dominant Polycystic Kidney Disease. *Clin J Am Soc Nephrol*. 2012;7(2):248-57. <https://pubmed.ncbi.nlm.nih.gov/22193235/>
28. Yaddanapudi S, Altintas MM, **Kistler AD**, Fernandez I, Möller CC, Wei C, Peev V, Flesche JB, Forst AL, Li J, Patrakka J, Xiao Z, Grahammer F, Schiffer M, Lohmüller T, Reinheckel T, Gu C, Huber TB, Ju W, Bitzer M, Rastaldi MP, Ruiz P, Tryggvason K, Shaw AS, Faul C, Sever S, Reiser J. CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survival. *J Clin Invest*. 2011;121(10):3965-80. <https://pubmed.ncbi.nlm.nih.gov/21911934/>
29. Nijenhuis T, Sloan AJ, Hoenderop JG, Flesche J, van Goor H, **Kistler AD**, Bakker M, Bindels RJ, de Boer RA, Möller CC, Hamming I, Navis G, Wetzels JF, Berden JH, Reiser J, Faul C, van der Vlag J. Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway. *Am J Pathol*. 2011;179(4):1719-32. <https://pubmed.ncbi.nlm.nih.gov/21839714/>
30. **Kistler AD**, Siwy J, Breunig F, Jeevaratnam P, Scherl A, Mullen W, Warnock DG, Wanner C, Hughes DA, Mischak H, Wüthrich RP, Serra AL. A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapy. *PLoS One*. 2011;6(6):e20534. <https://pubmed.ncbi.nlm.nih.gov/21698285/>

31. Bolliger MF, Zurlinden A, Lüscher D, Bütikofer L, Shakhova O, Francolini M, Kozlov SM, Cinelli P, Stephan A, **Kistler AD**, Rüllicke T, Pelczar P, Ledermann B, Fumagalli G, Gloor SM, Kunz B, Sonderegger P. Specific proteolytic cleavage of agrin regulates the maturation of the neuromuscular junction. *J Cell Sci.* 2010;123(22):3944-55. <https://pubmed.ncbi.nlm.nih.gov/20980386/>
32. Pavik I, Jaeger P, **Kistler AD**, Poster D, Krauer F, Weder Cavelti C, Rentsch KM, Wüthrich RP, Serra AL. Elevated FGF23 levels in ADPKD patients with apparent renal leak of phosphate: A new manifestation of ADPKD. *Kidney Int.* 2011;79(2):234-40. <https://pubmed.ncbi.nlm.nih.gov/20944552/>
33. Serra AL, Poster D, **Kistler AD**, Krauer F, Raina S, Young J, Rentsch KM, Spanaus KS, Senn O, Kristanto P, Scheffel H, Weishaupt D, Wüthrich RP. Sirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney Disease. *N Engl J Med* 2010;363:820-829. <https://pubmed.ncbi.nlm.nih.gov/20581391/>
34. Serra AL, **Kistler AD**, Poster D, Krauer F, Senn O, Raina S, Pavik I, Rentsch K, Regeniter A, Weishaupt D, Wüthrich RP. Safety and tolerability of sirolimus treatment in patients with autosomal dominant polycystic kidney disease. *Nephrol Dial Transplant.* 2009;24(11):3334-42. <https://pubmed.ncbi.nlm.nih.gov/19525519/>
35. Poster D and **Kistler AD (equal contribution)**, Krauer F, Blumenfeld JD, Rennert H, Weishaupt D, Wüthrich RP, Serra AL. Kidney function and volume progression in unilateral autosomal dominant polycystic kidney disease with contralateral renal agenesis or hypoplasia: a case series. *Am J Kidney Dis.* 2009;54(3):450-8. <https://pubmed.ncbi.nlm.nih.gov/19515475/>
36. **Kistler AD**, Mischak H, Poster D, Dakna M, Wüthrich RP, Serra AL. Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease. *Kidney Int.* 2009;76(1):89-96. <https://pubmed.ncbi.nlm.nih.gov/19340089/>
37. **Kistler AD**, Poster D, Krauer F, Weishaupt D, Raina S, Senn O, Binet I, Spanaus K, Wüthrich RP, Serra AL. Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. *Kidney Int.* 2009;75(2):235-41. <https://pubmed.ncbi.nlm.nih.gov/18971924/>
38. Stephan A, Mateos JM, Kozlov SV, Cinelli P, **Kistler AD**, Hettwer S, Rüllicke T, Streit P, Kunz B, Sonderegger P. Neurotrypsin cleaves agrin locally at the synapse. *FASEB J.* 2008;22(6):1861-73. <https://pubmed.ncbi.nlm.nih.gov/18230682/>
39. Serra AL, **Kistler AD**, Poster D, Strucker M, Wüthrich RP, Weishaupt D, Tschirch F. Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSSE ADPKD study. *BMC Nephrol.* 2007;8:13. <https://pubmed.ncbi.nlm.nih.gov/17868472/>

## 2. Fallbeschreibungen (case reports)

---

1. Burgener S, Rochat P, Dollenmaier G, Benz G, **Kistler AD**, Fulchini R. Progression of COVID-19 in a Patient on Anti-CD20 Antibody Treatment: Case Report and Literature Review. *Case Rep Infect Dis.* 2022;2022:8712424. <https://pubmed.ncbi.nlm.nih.gov/35251723/>
2. Frei A, **Kistler AD**. Zu viel D(es Guten). *Swiss Med Forum.* 2018;18(43):885-888. <https://doi.org/10.4414/smfm.2018.03354>
3. Sandner D, Bundi B, Müller D, Müller MK, **Kistler AD**. Vom Paintball gezeichnet. *Praxis (Bern 1994).* 2018;107(15):845-847. <https://pubmed.ncbi.nlm.nih.gov/30043700/>



4. **Kistler AD**, Schwarz U, Dalmau J, Rudiger A. Laparoscopic epilepsy surgery. Intensive Care Med. 2010;36(2):367-8. <https://pubmed.ncbi.nlm.nih.gov/19760392/>
5. **Kistler AD**, Poster D, Wüthrich RP, Serra AL. Hydronephrosis in autosomal dominant polycystic kidney disease. Kidney Int. 2009;76(12):1297. <https://pubmed.ncbi.nlm.nih.gov/19946316/>
6. Hofbauer GF, Marcollo-Pini A, Corsenca A, **Kistler AD**, French LE, Wüthrich RP, Serra AL. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. Br J Dermatol. 2008;159(2):473-5. <https://pubmed.ncbi.nlm.nih.gov/18547304/>

### 3. Übersichtsarbeiten (Reviews)

---

1. **Kistler AD**, Salant DJ. Complement activation and effector pathways in membranous nephropathy. Kidney Int. 2024 Mar;105(3):473-483. <https://pubmed.ncbi.nlm.nih.gov/38142037/>
2. Diebold M, **Kistler AD**. Glomerulonephritis nach Corona- Impfung: Kausalität oder Koinzidenz? Leading Opinions Innere Medizin, April 2023
3. **Kistler AD**. Das erhöhte Kreatinin: wann und wie abklären? Leading Opinions Innere Medizin, August 2021
4. Diebold M, **Kistler AD**. CME: Abklärung bei Hypokaliämie. Praxis (Bern 1994). 2019;108(3):207-213. <https://pubmed.ncbi.nlm.nih.gov/30838955/>
5. **Kistler AD**. Kontrastmittelnephropathie – viel Lärm um nichts? Leading Opinions Innere Medizin, 2019;3:54.
6. Seeger H , **Kistler AD**. Nephrologische Diagnostik mit der Toolbox des Hausarztes. Ther Umsch. 2018;75(6):335-343. <https://pubmed.ncbi.nlm.nih.gov/30880620/>
7. Flury S, **Kistler AD**. (Wie) kann die Progression chronischer Nierenerkrankungen verlangsamt werden? Ther Umsch. 2018;75(6):345-353. <https://pubmed.ncbi.nlm.nih.gov/30880619/>
8. Diebold M, **Kistler AD**. Röntgenkontrastmittel – zu Unrecht verteufelt? Ther Umsch. 2018;75(6):359-364. <https://pubmed.ncbi.nlm.nih.gov/30880616/>
9. **Kistler AD**, Andreisek G. Recommendations for Diagnostic and Prognostic Evaluation of Autosomal Dominant Polycystic Kidney Disease (ADPKD) with a Focus on Imaging. Praxis (Bern 1994). 2018 Jan;107(3):158-164. <https://pubmed.ncbi.nlm.nih.gov/29382260/>
10. **Kistler AD**, Bonny O, Fuster D, Martin PY, Devuyst O. Zulassung von Tolvaptan (Jinarc®) in der Schweiz zur Behandlung der Autosomal Dominanten Polyzystischen Nierenerkrankung (ADPKD): ein Paradigmenwechsel. Schweiz Med Forum 2017;17(14):336-339. <https://doi.org/10.4414/smf.2017.02906>
11. Lüthi L, **Kistler A**, Nowak A. CME: Hyperkaliämie bei Patienten mit chronischer Hämodialyse. Praxis (Bern 1994). 2017;106(11):561-570. <https://pubmed.ncbi.nlm.nih.gov/28537111/>
12. **Kistler AD**. Paraneoplastische membranöse Nephropathie. Nepro-News 2016;6:9
13. **Kistler AD**. Chronische Niereninsuffizienz: Wie lässt sich die Progression verhindern? Hausarzt Praxis 2016;11(12):35-38
14. **Kistler AD**. Das atypische hämolytisch-urämische Syndrom (aHUS): neue Erkenntnisse zur Pathogenese mit Implikationen für die Therapie. Praxis (Bern 1994). 2016;105(7):389-96. <https://pubmed.ncbi.nlm.nih.gov/27005733/>

15. **Kistler AD**. Interstitielle Nephritis. Swiss Medical Forum 2016;16(5):108-113. <https://doi.org/10.4414/smf.2016.02548>
16. **Kistler AD**, Huynh-Do U. Lupusnephritis. Rheuma Schweiz 2016;1:26-30.
17. Bock A, Jehle AW, Fischer A, Farese S, **Kistler AD**, Meffert G, Schönholzer C, Müller R, Spirk D, Ambühl P. CKD-MBD: Was tun, wenn die Evidenz fehlt? Schweiz Med Forum 2015;15(38):848-851. <https://doi.org/10.4414/smf.2015.02380>
18. Wüthrich RP, **Kistler AD**. Blutdruckkontrolle bei Patienten mit polyzystischer Nierenerkrankung. Der Nephrologe 2015(3);10:201-6. <https://doi.org/10.1007/s11560-014-0944-3>
19. **Kistler AD**. Lupusnephritis. Ther Umsch. 2015;72(3):171-7. <https://pubmed.ncbi.nlm.nih.gov/25722310/>
20. **Kistler AD**, Wüthrich RP. Welche Therapien können die Progression der chronischen Niereninsuffizienz wirksam verlangsamen? Swiss Medical Forum, 2015;15(11):251-256. <https://doi.org/10.4414/smf.2015.02190>
21. Daikeler T, **Kistler AD**, Martin P-Y, Vogt B, Huynh-Do U. The role of rituximab in the treatment of ANCA-associated vasculitides (AAV). Swiss Med Wkly. 2015;145:w14103. <https://pubmed.ncbi.nlm.nih.gov/25658140/>
22. **Kistler AD**. Update Lupusnephritis - Pathologie, Diagnose, Therapie. Leading Opinions Innere Medizin 2013;5:49-51
23. Heeringa S, **Kistler AD**. Utility of Urinary Biomarkers in Fabry Disease. CML – Lysosomal Storage Diseases 2013;11(4):108-17
24. **Kistler AD**. Albuminurie beim Diabetiker: praktisches Management. Praxis (Bern 1994). 2013;102(20):1229-35. <https://pubmed.ncbi.nlm.nih.gov/24088233/>
25. **Kistler AD**, Serra AL. Zystische Nierenerkrankungen: neue diagnostische Aspekte. Der Nephrologe. Der Nephrologe 2010;5(5):375-83. <https://doi.org/10.1007/s11560-010-0420-7>
26. Wüthrich RP, **Kistler AD**, Serra AL. Inhibition of mTOR and impact on autosomal dominant polycystic kidney disease. Transplant Proc. 2010;42(9 Suppl):S44-6. <https://pubmed.ncbi.nlm.nih.gov/21095452/>
27. **Kistler AD**, Peev V, Forst AL, El Hindi S, Altintas MM, Reiser J. Enzymatic disease of the podocyte. Pediatr Nephrol. 2010;25(6):1017-23. <https://pubmed.ncbi.nlm.nih.gov/20130922/>
28. Reiser J, Gupta V, **Kistler AD**. Toward the development of podocyte-specific drugs. Kidney Int. 2010;77(8):662-8. <https://pubmed.ncbi.nlm.nih.gov/20130528/>
29. Wüthrich RP, Serra AL, **Kistler AD**. Autosomal dominant polycystic kidney disease: new treatment options and how to test their efficacy. Kidney Blood Press Res. 2009;32(5):380-7. <https://pubmed.ncbi.nlm.nih.gov/19887826/>

#### 4. Buchbeiträge

---

1. Seeger H, **Kistler A**, Kamath N, Iyengar A. Infection related glomerulonephritis. In: Brenner and Rector's The Kidney, 12<sup>th</sup> Edition, Elsevier 2025 (in press)
2. **Kistler AD** und Gaspert A. Kapitel «Niere» in: Pathomaps, 2. Auflage, Springer, 2023. <https://doi.org/10.1007/978-3-662-64927-5>
3. **Kistler AD** und Brandt S. Kapitel «Niere» in: Pathomaps, Springer, 2019. <https://doi.org/10.1007/978-3-662-57439-3>
4. Wüthrich RP, **Kistler AD**, Rodriguez D, Kapoor S, Mei C. Blood Pressure Control for Polycystic Kidney Disease, In Li X, editor. Polycystic Kidney Disease [Internet]. Brisbane (AU):

Codon Publications; 2015 Nov. Chapter 5. <https://pubmed.ncbi.nlm.nih.gov/27512778/>

5. **Kistler AD.** Traditional and Proteomic Biomarkers of Autosomal Dominant Polycystic Kidney Disease (ADPKD). In: Preedy V., Patel V. (eds) General Methods in Biomarker Research and their Applications. Springer, Dordrecht. [https://doi.org/10.1007/978-94-007-7740-8\\_48-1](https://doi.org/10.1007/978-94-007-7740-8_48-1)

## 5. Monographien

---

1. **Andreas Kistler.** Die Kostenexplosion im Gesundheitswesen. Wie das System zum Patienten wird. NZZ LIBRO 2025

## 6. Angeleitete Dissertationen

---

1. Accuracy of Flash Glucose Monitoring in Hemodialysis Patients With and Without Diabetes Mellitus. Inaugural-Dissertation an der Medizinischen Fakultät der Universität Zürich von Michèle Rebecca Weber

## 7. Sonstige wissenschaftliche Publikationen

---

1. **Kistler AD.** Function follows form: the quest for the best prognostic imaging biomarker in ADPKD. Kidney Int. 2023 Aug;104(2):239-241. (Editorial) <https://pubmed.ncbi.nlm.nih.gov/37479385/>
2. Diebold M, **Kistler AD.** Does hemodialysis patient awareness of upcoming routine laboratory sampling temporarily influence adherence? Hemodial Int. 2020 Oct;24(4):550-551. (Letter presenting original research). <https://pubmed.ncbi.nlm.nih.gov/32770611/>
3. **Kistler AD.** Niereninsuffizienz – eine verborgene Epidemie. Ther Umsch. 2018;75(6):333. (Editorial zu einer als Gastherausgeber gestalteten Ausgabe) <https://pubmed.ncbi.nlm.nih.gov/30880618/>
4. **Kistler AD.** Eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;369(14):1378. (Letter to the Editor) <https://pubmed.ncbi.nlm.nih.gov/24088108/>
5. **Kistler AD,** Altintas MM, Reiser J. Podocyte GTPases regulate kidney filter dynamics. Kidney Int. 2012;81(11):1053-5. (Editorial) <https://pubmed.ncbi.nlm.nih.gov/22584591/>
6. **Kistler AD,** Faul C, Reiser J. TRPC6 in podocytes: questions and commentary on the article by Jiang et al., 'Over-expressing transient receptor potential cation channel 6 in podocytes induces cytoskeleton rearrangement through increases of intracellular Ca<sup>2+</sup> and RhoA activation'. Exp Biol Med (Maywood). 2011;236(12):1361. (Letter to the Editor) <https://pubmed.ncbi.nlm.nih.gov/22242226/>
7. **Kistler AD,** Reiser J. Maximal "CD80-uria" with Minimal Change. Kidney Int. 2010;78(3):236-8. (Editorial) <https://pubmed.ncbi.nlm.nih.gov/20631735/>